Keyword: Ninlaro

Takeda expects Velcade sales to drop more than 30% this year, but it's hoping newer drugs Ninlanro and Entyvio help fill the gap.

Lilly will close its Shanghai R&D center, OrbiMed sets up its third Asia healthcare fund, and Takeda marches into CAR-T with a new deal.

Takeda's CEO has said Ninlaro would surpass blockbuster Velcade as the company’s biggest-ever cancer product. But NICE could get in the way.

Takeda's blockbuster cancer med Velcade, previously set for copycat competition this year, won an appeals court ruling preserving sales for years.

With a patent loss looming, Takeda filed a citizen petition pushing the FDA to knock back generic Velcade competition.

Nanjing Legend Biotech reported 100% ORR for a CAR-T product, Chi-Med touted fruquintinib's low liver toxicity, Eisai's Lenvima could challenge Bayer's Nexavar and more.

Takeda is starting work on a €40 million plant to manufacture multiple myeloma drug Ninlaro at its site in Ireland, where it will add 40 new jobs.

In this week's FiercePharmaAsia wrap-up, Takeda and VC Lightstone have joined forces in forming a neuroscience startup, China's cancer research is narrowing the U.S. lead, Sun's Halol plant was hit by FDA notice again, and more.

Japan’s Takeda, which expects its new multiple myeloma drug to be a big performer, is expanding API production for it with a new plant in Ireland. 

Out of the three new multiple myeloma therapies to win FDA approval last year, only Johnson & Johnson’s Darzalex was relegated to the fourth-line setting. But no longer.